Fig. 2

The lipids characteristics of the validation set. a PAF synthesis pathway. b ROC analysis for LPC(16:0) (AUC: 0.9833, 95% confidence interval: 0.9322–1.0000). c Typical chromatograms of TIC in plasma samples from comparative efficacy group. d Score plot of PCA based on the data of ESI⁺ mode from comparative efficacy group. e Score plot of OPLS-DA based on the data of ESI⁺ mode from comparative efficacy group. f Volcano plot based on the data of ESI⁺ mode from comparative efficacy group. g–i Changes of LPC(O-24:0), LPC(20:4) and LPC(16:1/0:0) contents in plasma of comparative efficacy group. j Heatmap showed that LPC(O-24:0), LPC(20:4) and LPC(16:1/0:0) were significantly increased that were identified from the comparison of R vs NR. k The mRNA level of LPCAT1 in bone marrow plasma cells from NP (n = 22), MGUS (n = 44) and MM (n = 500). LPCAT1 expression was significantly increased in MM samples by ordinary one-way ANOVA test. l–n High LPCAT1 expression in MM patients was correlated with poor OS in TT2 cohort, HOVON-65 clinical trial and APEX phase III clinical trial by log-rank test. o The expression of LPCAT1 mRNA at baseline (previously published under GSE2685, n = 351) and relapse patients (n = 130). LPCAT1 expression was markedly increased in the relapsed MM patients by log-rank test. (*p < 0.05, **p < 0.01)